SIRT6 safeguards human mesenchymal stem cells from oxidative stress by coactivating NRF2.
Pan H, Guan D, Liu X, Li J, Wang L, Wu J, Zhou J, Zhang W, Ren R, Zhang W, Li Y, Yang J, Hao Y, Yuan T, Yuan G, Wang H, Ju Z, Mao Z, Li J, Qu J, Tang F, Liu GH. · 2016
Read SIRT6 safeguards human mesenchymal stem cells from oxidative stress by coactivating NRF2. by Pan H, Guan D, Liu X, Li J, Wang L, Wu J, Zhou J, Zhang W, Ren R, Zhang W, Li Y, Yang J, Hao Y, Yuan T, Yuan G, Wang H, Ju Z, Mao Z, Li J, Qu J, Tang F, Liu GH. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4746611.txt.
Introduction
Pan and 21 colleagues test whether SIRT6, a longevity-linked enzyme, directly protects human mesenchymal stem cells, the tissue-repair cells whose decline marks aging of bone, cartilage, and fat. They delete SIRT6 from human stem cells using targeted gene editing and watch the cells fail early.
The loss does not destabilise chromosomes. Instead it scrambles redox balance and leaves the cells fragile under oxidative stress. SIRT6 normally partners with the master antioxidant regulator NRF2 and the transcription machinery to switch on protective genes such as HO-1. Restoring HO-1 alone rescues much of the premature decline, identifying the SIRT6-NRF2 axis as a guardian of stem cell health.
Catalog record
| CREATOR | Pan H, Guan D, Liu X, Li J, Wang L, Wu J, Zhou J, Zhang W, Ren R, Zhang W, Li Y, Yang J, Hao Y, Yuan T, Yuan G, Wang H, Ju Z, Mao Z, Li J, Qu J, Tang F, Liu GH. |
|---|---|
| YEAR | 2016 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
SIRT6 safeguards human mesenchymal stem cells from oxidative stress by coactivating NRF2 By Huize Pan, Di Guan, Xiaomeng Liu, Jingyi Li, Lixia Wang, Jun Wu, Junzhi Zhou, Weizhou Zhang, Ruotong Ren, Weiqi Zhang, Ying Li, Jiping Yang Published in: Cell Research DOI: 10.1038/cr.2016.4 ABSTRACT SIRT6 belongs to the mammalian homologs of Sir2 histone NAD+-dependent deacylase family. In rodents, SIRT6 deficiency leads to aging-associated degeneration of mesodermal tissues. It remains unknown whether human SIRT6 has a direct role in maintaining the homeostasis of mesodermal tissues. To this end, we generated SIRT6 knockout human mesenchymal stem cells (hMSCs) by targeted gene editing. SIRT6-deficient hMSCs exhibited accelerated functional decay, a feature distinct from typical premature cellular senescence. Rather than compromised chromosomal stability, SIRT6-null hMSCs were predominately characterized by dysregulated redox metabolism and increased sensitivity to the oxidative stress. In addition, we found SIRT6 in a protein complex with both nuclear factor erythroid 2-related factor 2 (NRF2) and RNA polymerase II, which was required for the transactivation of NRF2-regulated antioxidant genes, including heme oxygenase 1 (HO-1). Overexpression of HO-1 in SIRT6-null hMSCs rescued premature cellular attrition. Our study uncovers a novel function of SIRT6 in maintaining hMSC homeostasis by serving as a NRF2 coactivator, which represents a new layer of regulation of oxidative stress-associated stem cell decay. INTRODUCTION Stem cell exhaustion is considered as one of the hallmarks of aging1,2. Mesenchymal stem cells (MSCs) are adult stem cells with the potential of differentiation into mesodermal lineages, such as osteoblasts, chondrocytes, and adipocytes3, and play an important role in tissue regeneration4. Aged human and animals exhibit decreased number or diminished proliferative potential of MSCs5,6. Accelerated attrition of MSC pool has been observed in human stem cell and mouse models for human premature aging disorders, including Werner syndrome (WS) and Hutchinson Gilford progeria syndrome7,8,9,10. Transplantation of mesoderm-derived stem cells from young mice increases the lifespan and fitness of progeroid mice11,12. While MSC exhaustion is known as a culprit for aging-associated degeneration of mesodermal tissues1, the underlying genetic pathways employed by human MSCs (hMSCs) to maintain homeostasis have not been fully elucidated. A number of intracellular and intercellular factors are known to maintain stem cell homeostasis13,14 and one of such factors is reactive oxygen species (ROS)5. ROS is normally maintained at a balanced level by cellular antioxidant systems15. Nuclear factor erythroid 2-related factor 2 (NRF2) is a critical redox sensor and is one of the master regulators of antioxidant responses. NRF2 binds to the antioxidant response elements (AREs) and activates the transcription of a number of antioxidant genes such as heme oxygenase 1 (HO-1) that is known for counteracting ROS16. The decline in NRF2-ARE activity is observed in aged cells, and may account for the oxidative stress-associated tissue degeneration17,18. The key factors regulating NRF2 antioxidant pathway in hMSCs, however, remain to be identified. SIRT6 is one of the seven mammalian sirtuin homologues of yeast Sir2 longevity protein19. Sirt6-deficient mice suffered from multiple acute premature aging syndromes, which ultimately led to premature death within 1 month after birth20. SIRT6 contains a domain with NAD+-dependent deacetylase activity21,22, which accounts for transcriptional repression of target genes such as NF-κB, HIF1α, and c-JUN by deacetylating histone H3 lysine 9 (H3K9) at the gene promoters23,24,25. In addition, silencing SIRT6 in fibroblasts leads to the accelerated cellular senescence possibly due to attenuated deacetylation of H3K9 at the telomere region26. SIRT6 is also involved in DNA damage repair by deacetylation of H3K56 at the damaged DNA region27,28,29. Recently, evidence has emerged that SIRT6 protects cells from oxidative stress-associated DNA damage21, raising a possibility that SIRT6 could be involved in redox-related cellular homeostasis regulation. Here we demonstrate that SIRT6 is a positive modulator of NRF2-HO-1 antioxidant pathway in hMSCs, a novel mechanism implicated in safeguarding stem cells from oxidative stress-associated functional decay. RESULTS SIRT6-depleted hMSCs exhibit accelerated functional decay To study the role of SIRT6 in hMSCs, we first generated SIRT6-deficient human embryonic stem cells (hESCs). The exon 1 of SIRT6 gene was removed in hESCs by a transcription activator-like effector nuclease (TALEN)-mediated homologous recombination strategy30,31,32 (Figure 1A). Biallelic loss of SIRT6 in SIRT6−/− hESCs was confirmed by genomic PCR and Southern blotting (Supplementary information, Figure S1A and S1B). Loss of mRNA and protein in SIRT6−/− hESCs was verified by reverse transcription-PCR (RT-PCR) and western blotting, respectively (Figure 1B). Immunofluorescence staining demonstrated a punctate staining pattern of SIRT6 in the nuclei of wild-type (WT) hESCs, which was absent in SIRT6−/− hESCs (Figure 1C). The SIRT6-deficient hESCs were cultured for more than 50 passages without discernible morphological abnormality and still exhibited defining characteristics of pluripotency, including the expression of pluripotency markers and the in vivo differentiation potential towards three germ layer lineages (Supplementary information, Figure S1C and S1D). Given that tissue stem cell exhaustion has been recently recognized as one of the hallmarks of aging10, and the Sirt6-deficient mice exhibit features of premature aging in mesodermal tissues20, we hypothesized that SIRT6 deficiency would result in accelerated attrition of hMSC pool. We thus differentiated the SIRT6−/− and WT hESCs into hMSCs. SIRT6−/− and WT hMSCs expressed typical hMSC markers such as CD73, CD90, and CD105 (Figure 1D), and were found negative for hMSC irrelevant antigens CD45, CD34 and CD43 (Supplementary information, Figure S1E)10,31. RT-qPCR and western blotting results confirmed the loss of both SIRT6 mRNA and protein in SIRT6−/− hMSC (Figure 1E and Supplementary information, Figure S1F). Immunofluorescence indicated a relatively diffused localization pattern of SIRT6 in the nuclei of WT hMSCs, which was absent in the SIRT6−/− hMSCs (Figure 1F). As the Sirt6-deficient mice exhibited bone abnormalities20, we wondered whether the differentiation potential was compromised in SIRT6−/− hMSCs. As expected, compared with WT hMSCs, SIRT6−/− hMSCs exhibited substantially impaired differentiation towards osteoblasts or chondrocytes (Supplementary information, Figure S1G). Next, we investigated the link between SIRT6 and hMSC aging. Although serial passaging of SIRT6−/− hMSCs led to several observations implicated in premature senescence such as early onset of senescence-associated (SA)-β-Gal activity (Figure 1G), upregulation of P16 and P21 proteins33 (Figure 1H), and progressive impairment in cell proliferation ability (Supplementary information, Figure S1H), SIRT6−/− hMSCs also exhibited features distinct from hMSCs derived from premature aging patients10. For instance, different from WS-specific hMSCs10, decreased transcripts from centromeric repetitive sequences34, and a mild but significant increase of G2/M population were observed in SIRT6−/− hMSCs (Supplementary information, Figure S1I and S1J). We ruled out the possibility that the premature aging phenotypes observed in SIRT6−/− hMSCs resulted from chromosomal instability as reported in mouse study20, as SIRT6−/− hMSCs exhibited normal karyotypes and minimal genomic mutational load determined by genome-wide copy number variation (CNV) analysis (Supplementary information, Figure S2A and S2B). Moreover, no significant increase in DNA damage response marker γH2AX was observed in SIRT6−/− hMSCs (Supplementary information, Figure S2C and S2D). Finally, we investigated whether SIRT6−/− hMSCs suffered from accelerated functional decay in an in vivo niche by transplanting WT and SIRT6−/− hMSCs into tibialis anterior (TA) muscle of the immunodeficient mice10. Compared with WT hMSCs, an accelerated in vivo decay of SIRT6−/− hMSCs was observed after engraftment (Figure 1I, Supplementary information, Figure S2E and S2F). The attrition of SIRT6−/− hMSCs could be alleviated by lentiviral vector-mediated reconstitution of exogenous SIRT6 (Supplementary information, Figure S2G). Altogether, these results support that SIRT6 has